Current Report Filing (8-k)
August 23 2019 - 11:36AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
August 20, 2019
Titan
Pharmaceuticals, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
001-13341
|
94-3171940
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
400
Oyster Point Blvd., Suite 505, South San Francisco, CA 94080
|
(Address of principal executive offices and zip code)
|
|
650-244-4990
|
(Registrant's telephone number including area code)
|
|
|
(Registrant's former name or former address, if changed since last report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12(b) under
the Exchange Act (17 CFR 240.14a-12(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001
|
|
TTNP
|
|
Nasdaq Capital Market
|
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.
On August 20, 2019, Titan Pharmaceuticals, Inc. (the “Company”)
received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company
that it is no longer in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq
Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2,500,000.
The letter noted that the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2019 (the “10-Q”)
reported stockholders’ deficit of $(571,000).
As previously announced and reflected in the 10-Q, in August
2019 the Company completed an equity financing that resulted in net proceeds of approximately $1.8 million. The Company is diligently
pursuing additional avenues that will further positively impact stockholders’ equity.
The notification letter has no immediate effect on the Company’s
listing on the Nasdaq Capital Market. Nasdaq has provided the Company with 45 calendar days, or until October 4, 2019, to submit
a plan to regain compliance with the minimum stockholders’ equity standard. If the Company’s plan to regain compliance
is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the notification letter to regain compliance.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
TITAN PHARMACEUTICALS, INC.
|
|
|
|
|
By:
|
/s/ Sunil Bhonsle
|
|
Name:
|
Sunil Bhonsle
|
|
Title:
|
Chief Executive Officer and President
|
Dated: August 23, 2019
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Titan Pharmaceuticals (NASDAQ:TTNP)
Historical Stock Chart
From Apr 2023 to Apr 2024